Establishment Labs Holdings Inc. (ESTA) Income Statement

The reported growth rate has moved from low double digits in early 2025 to above 30% in the most recent periods, which may indicate improving surgeon adoption of the Motiva platform outside the United States. Because the figures reflect no US revenue, the durability of this trajectory depends on whether international ASPs and distributor volumes remain stable. Investors should monitor whether growth holds as the base expands, since reliance on a limited set of geographies could make growth more sensitive to regional regulatory or pricing shifts.

Stability of gross margin across rapid revenue expansion suggests that production scaling has not materially eroded unit economics. This pattern is consistent with a differentiated product rather than a commoditized implant, though the figures alone cannot confirm pricing power versus peers. A margin near 70% provides substantial headroom, but a shift toward lower-ASP international mix could compress this figure without warning.

The compression in operating losses implies genuine operating leverage as revenue has grown faster than the SG&A and R&D base. However, the operating line remains negative in every reported quarter, so the leverage has not yet translated into profitability. Investors should watch whether operating margin turns positive before US launch cost ramps, as that timing will likely determine how much external funding may be required.

R&D at $4.3M per quarter is comparatively small, which suggests spending is weighted toward commercial infrastructure rather than pipeline development at the reported level. This structure is consistent with a company building a direct sales footprint ahead of potential market expansion, though the figures do not disclose the split between maintenance and growth spending. Monitoring SG&A as a percentage of revenue will be the clearest indicator of whether cost discipline is improving alongside top-line growth.